1. Introduction {#s0005}
===============

1.1. Purpose and mission {#s0010}
------------------------

A deeper knowledge of the impact of neuropathology on the neuroanatomical circuitry in the aging human brain is required to understand why some people develop highly disabling neurological conditions, whereas others remain neurologically (and mentally) unimpaired until the age of 100 years or more ([@bb0010]). Well-characterized, high-quality brain tissue of non-neurological control subjects is a prerequisite to study the healthy aging brain, and can serve as a control for the study of neurological disorders. Nevertheless, high-quality post-mortem brain tissue samples of controls without neurological or mental disorders are sparse. To combine willed body donation for medical education and brain donation for research with the same donor, is an efficient opportunity to address both (education and research) needs. Although research groups have included post-mortem MRI in their studies, most notable in the case of patient H.M. ([@bb0035]), to our knowledge, none of the brain banks worldwide have high-field, whole-brain post-mortem *in situ* magnetic resonance imaging (MRI) data in combination with high quality brain tissue available for scientific research ([@bb0095]; [@bb0125]; [@bb0130]; [@bb0150]; [@bb0155]; [@bb0235]; [@bb0245]; [@bb0250]; [@bb0255]; [@bb0285]; [@bb0295]; [@bb0315]).

The Normal Aging Brain Collection Amsterdam (NABCA) answers to this need by providing a comprehensive collection of post-mortem (ultra-)high-field MRI (3Tesla and 7 Tesla) and neuropathological datasets of non-neurological controls. By direct coupling of postmortem MRI and tissue as intrinsic elements of the NABCA collection, we aim to provide the scientific community with a means to translate molecular, cellular, histopathological and brain imaging knowledge to the clinical setting.

NABCA objectives can be summarized as follows:-Provide the neuroscientific research community (worldwide) with crucially needed, excellently documented, high-quality MRI data and brain tissue of non-neurological controls, for studies of a wide variety of neurological disorders;-Lay the national foundation for studies of healthy aging, based on a collection of stringently collected brain tissue from 18 to 90 years old;-Stimulate and innovate translational neurosciences (*i.e.*, translation from molecular and morphometric tissue studies to the clinical setting, *via* advanced post-mortem MR imaging);-Develop educational neuroanatomical, histopathological and neuroradiological packages for professionals, students and the general (lay) audience.

We have developed a protocol to collect brains of non-neurological donors with a short (4 h--12 h) post-mortem interval (PMI), in combination with uniform and comprehensive characterization with MRI, and histopathology.

1.2. Research site, study population and ethical approval {#s0015}
---------------------------------------------------------

NABCA is embedded within the department of Anatomy and Neurosciences, Amsterdam Neuroscience, VU University medical center (VUmc). This department has the privilege of administering the human body bequest program. The process of accepting and managing bequests is governed by the human tissue act ('ter beschikking stelling', Artikel 18, lid 1 en 19 van de Wet op de Lijkbezorging, 1991), which allows body donation to facilitate medical research and education. Donors above the age of 18 are eligible to the human body bequest program at VUmc and approximately \~2200 donors are currently registered. In collaboration with the mortuary, NABCA includes \~10 donors a year in the rapid MRI-autopsy pipeline, based on in [Section 2.2](#s0030){ref-type="sec"} mentioned inclusion/exclusion criteria. All medical research on human subjects is ethically and legally guided by the Declaration of Helsinki (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>). Additionally, NABCA has obtained approval of our institutional ethical review board for all aspects of the pipeline.

2. Autopsy pipeline {#s0020}
===================

Various autopsy pipelines have previously been described (*e.g.*[@bb0040]; [@bb0045]; [@bb0265]). However, NABCA has developed a pipeline that includes *in situ* 3 T and *ex vivo* 7 T MRI as standard practice (see [Fig. 1](#f0005){ref-type="fig"} for an overview). In brief, it starts with donor selection for post-mortem *in situ* 3 T MRI based on age, cause of death and post-mortem delay. The 3 T MRI is evaluated by a neuroradiologist for radiological abnormalities suggestive of neurological disease. After MRI, craniotomy takes place and the brain is photographed and evaluated by a neuropathologist, the weight is noted and fresh snap-frozen tissue excision is performed on the left hemisphere based on an extensive standardized protocol. The right hemisphere is placed in 4% formalin for four weeks, then *ex vivo* scanned at 7 T MRI, and subsequently dissected. In total 35 formalin fixed tissue blocks are collected and embedded in paraffin, the remaining brain tissue is kept in formalin. Histological and immunostained sections of 15 brain regions are evaluated for neuropathological diagnosis, all according to strict standardized protocols in line with BrainNet Europe (BNE) ([@bb0030]; [@bb0025]; [@bb0020]). After *in situ* MRI and further brain autopsy, the body is returned to the Anatomy and Neurosciences morgue for further enrolment in the body donation program for education and scientific research. Since 2014, NABCA has so far included over 40 donors. We will explain each of the pipeline aspects in the following paragraphs.Fig. 1Overview of NABCA pipeline. Starting with donor selection based on available criteria, an *in situ* MRI is performed. The scan protocol includes a 3D-T1w, PD/T2w and FLAIR sequence (a radiological report of the *in situ* MRI is provided by an experienced radiologist in the days after the scan). After the *in situ* MRI, craniotomy takes place at autopsy, the brain is cut in half; the left hemisphere is dissected in \~80 tissue blocks for molecular and/or biochemical analysis, the right hemisphere is put in 4% formalin. After four weeks, *ex vivo* 7 T MRI is performed on the right hemisphere. The scan protocol includes a 3D-T1w, 3D FLAIR and T2\*w sequence. Subsequently the right hemisphere is dissected in 35 tissue blocks for paraffin embedding. Fifteen tissue blocks are then used for a full pathological report provided by an experienced neuropathologist. After this, the non-neurological data is ready for distribution after completion of an application form, approval from the scientific advisory board and institutional review board, and signing of a material transfer agreement (MTA).The NABCA pipeline has been approved by local ethical committee.Fig. 1

2.1. On call MRI and autopsy teams {#s0025}
----------------------------------

Previous molecular and biochemical studies using postmortem brain tissue have indicated that post-mortem interval (PMI) has an influence on brain tissue quality ([@bb0055]; [@bb0100]; [@bb0250]), it therefore is crucial to keep the time between death and autopsy to a minimum. This can only be achieved by the maintenance of a team that is readily available in case of an autopsy. Before team members become a part of the on-call team, they are trained by means of an extensive introduction and attending an autopsy without assisting. Subsequently, they assist an experienced team member and finally they will join the team as full members. Ongoing meetings are organized to evaluate training needs of team members. For safety and efficiency, at each callout one MRI operator and two autopsy assistants are required. MRI operators and autopsy assistants rotate through a weekly on-call schedule that is planned two months ahead. The neuropathologists have their own on-call schedule at the department of pathology in accordance to other brain banking duties. To expedite the workflow, an autopsy kit is prepared in advance; containers and cassettes are labelled and equipment is laid out ready for use.

2.2. Donor in/exclusion and clinical information {#s0030}
------------------------------------------------

According to the human tissue act, the family of the deceased has up to 24 h to release the body. NABCA only receives a notification (from the VUmc, Anatomy and Neurosciences morgue) if the donor can be at the VUmc morgue within seven hours after death. An exclusion criterion is the cause of death being a neurological or mental disorder, including sepsis, encephalitis, asphyxia, a cerebrovascular accident or traumatic brain injury. Cases with a medical history of neurological or psychiatric diagnosis are excluded too. Furthermore, NABCA focuses on collecting donors above 18 and below 90 years of age. A last exclusion criteria is the presence of neuropathological change at pathological assessment, which will be discussed in [Section 2.6](#s0060){ref-type="sec"}.

2.3. Post-mortem *in situ* 3 T MRI and radiological assessment {#s0035}
--------------------------------------------------------------

When a donor has been included, first an *in situ* MRI (brain still in cranium) is performed on a 3 T whole body scanner (General Electric Signa MR750) using an eight-channel phased-array head coil. The scan protocol (\~45 min) is optimized for the post-mortem setting and includes an axial 2D proton density/T2-weighted (PD/T2w) sequence for clinical reference and pathological-anatomical differentiation, a sagittal 3D fluid attenuated inversion recovery (FLAIR) sequence to visualize possible (vascular-ischemic) white and gray matter pathology, a sagittal 3D T1w fast spoiled gradient echo (FSPGR) sequence for gray/white matter differentiation; enabling the study of regional volumes, cortical thickness and shapes, a susceptibility-weighted (T2\*w) sequence for iron deposits and microbleeds, and an axial 2D diffusion tensor imaging (DTI; separate reference images with reversed phase encoding directions to estimate and correct susceptibility induced distortions) sequence for microstructural analysis and structural connectivity. See [Table 1](#t0005){ref-type="table"} for sequence details and [Fig. 2](#f0010){ref-type="fig"} for an example of images. Aside from general post-mortem optimizations, the FLAIR contrast depends on optimal suppression of CSF. However, due to differences in post-mortem delay and brain temperature, T1 relaxation times differ. Therefore, we measure a short series of FLAIR images with low spatial resolution to determine the optimal inversion time per case.Table 1Sequence details of 3 T *in situ* and 7 T *ex vivo* MRI sequences.Table 1Sequence3 T *in situ*7 T *ex vivo*PD/T23D T1wFLAIRDTIT2\*3D T13D FLAIRT2\*At different resolutionsRepetition Time (ms)4250780007400314.1800036363140Echo time (ms)22/115313092251.85298202025Inversion time (ms)--4502000--2250--------------Flip Angle (degrees)--15----157--------Acquisition resolution (mm)0.65 × 0.73 × 31x1x11.11 × 1.11 × 1.22×2×20.65 × 0.65 × 30.89 × 0.9 × 0.90.6 × 0.6 × 0.60.6 × 0.6 × 0.60.3 × 0.3 × 0.30.24 × 0.24 × 1Reconstructed resolution (mm)0.5 × 0.5 × 30.5 × 0.5 × 11x1x1.22×2×20.5 × 0.5 × 30.85 × 0.85 × 0.90.3 × 0.3 × 0.60.18 × 0.18 × 0.60.18 × 0.18 × 0.30.21 × 0.21 × 1Acquisition Time (h:m:s)4:415:075:394:195:001:411:20:0821:191:54:1213:18[^1][^2]Fig. 2Overview of images included in the NABCA *in situ* pipeline. Images A-H are from NABCA case 1, age 68, showing no pathological abnormalities, image I is from NABCA case 5, age 59, showing no pathological abnormalities (see [Table 3](#t0015){ref-type="table"}). A-C: sagittal 3D T1w image and reconstructed coronal and axial views, D-F: sagittal 3D FLAIR image and reconstructed coronal and axial views, G: axial 2D proton density (PD) image, H: corresponding axial 2D T2-w image, and I: axial 2D Susceptibility Weighted Image (SWI).Fig. 2

Independent from the autopsy (often the following day), the MRI examination is assessed by an experienced neuroradiologist. The radiological report includes presence of space occupying lesions or other focal/unexpected findings and assessment of atrophy; both global (scale 0--3) and local (scale 0--4), severity of white matter hyperintensities (Fazekas scale 0--3), number of (basal ganglia) lacunar and other infarctions ([@bb0110]; [@bb0320]).

Volumetric analysis of the *in situ* MRI images can be done with processing tools used *in vivo*, such as the FMRIB Software Library (FSL; version 5.0) ([@bb0175]). This includes removal of non-brain tissue (BET) on T1-weighted images, and tissue segmentation with SIENAX ([@bb0290]) from which normalized volumetric measures are obtained. Additionally, hippocampal volumes are measured with FIRST (also part of FSL ([@bb0175])). See [Table 3](#t0015){ref-type="table"} for the measurements of 5 non-neurological controls. These volumetric values fall within the range indicative for normal aging in *in vivo* studies ([@bb0170]; [@bb0270]).Table 3Demographics, pathological and MRI characteristics of included donors.Table 3IDCase 1Case 2Case 3Case 4Case 5Mean ± SDGenderMFFFF1 M/4FAge (y)687172775969.4 ± 5.9PMI (h:m)8:406:507:204:308:107:02 ± 1:34pH of CSF6.126.87n/a6.56.086.39 ± 0.32Pathological classification "ABC score"A1 B1 C0A1 B1 C0A0 B0 C0A1 B1 C0A0 B0 C0--Thal phase22020--Braak NFT10--1020--Braak a-syn00000--TDP-4300000--CAA00000--APOE-4E3/E4E3/E4E3/E3E3/E3E3/E3--MTA R/L0/00/10/01/20/0--GCA01011--Fazekas02122--lacunes00000--BG lacunes00000--Infarcts00000--NBV (L)[a](#tf0005){ref-type="table-fn"}1.611.481.511.501.461.51 ± 0.05NWMV (L)[a](#tf0005){ref-type="table-fn"}0.760.710.720.710.680.72 ± 0.03NGMV (L)[a](#tf0005){ref-type="table-fn"}0.850.770.800.780.780.80 ± 0.03Hippocampus right (ml)[b](#tf0010){ref-type="table-fn"}5.314.856.525.205.605.50 ± 0.57Hippocampus left (ml)[b](#tf0010){ref-type="table-fn"}5.065.216.354.245.675.31 ± 0.70[^3][^4][^5]

2.4. Post-mortem *ex vivo* 7 T MRI {#s0040}
----------------------------------

Back in the mortuary, craniotomy takes place and the brain is dissected into two halves; the left hemisphere is further dissected according to a snap frozen protocol (see paragraph 2.5.1), the right hemisphere is stored in 4% formalin.

A higher spatial resolution and signal to noise ratio can be achieved at higher field strengths and longer acquisition times. In addition, 7 T MRI provides unique image contrast compared to the conventional 3 T MRI, particularly for susceptibility-weighted contrast (T~2~^⁎^w or SWI). These susceptibility-weighted changes are closely related to myelin and iron allowing detection of cortical lamination and iron-associated pathology ([@bb0080]; [@bb0220]; [@bb0305]). Therefore, we include an *ex vivo* 7 T MRI scan, performed at LUMC (Leiden, the Netherlands) on a whole-body human 7 T MR system (Philips Healthcare, Best, the Netherlands) After four weeks of formalin fixation, the right hemisphere is rinsed with tap water for 24 h to partially restore the relaxation parameters ([@bb0280]). The hemisphere is subsequently sent to LUMC in Phosphate-buffered saline (PBS) and there placed in a plastic bag containing a proton-free fluid (Fomblin®, LC08, Solvay). To minimize the amount of trapped air bubbles, a vacuum is applied overnight. Before scanning, the plastic bag is sealed and fixed on a plastic plateau in the center of the quadrature transmit and 32-channel receiver head coil. The scan protocol (\~8 h) includes a coronal 3D T1w scan, and a sagittal 3D FLAIR. Several T~2~^⁎^w sequences are included with resolutions ranging from lower (0.6 × 0.6 × 0.6 mm) to higher (0.3 × 0.3 × 0.3 mm). We acquired *ex vivo* data at different resolutions in order to bridge the gap between *ex vivo* and *in vivo* MRI. *Ex vivo* MRI allows resolutions around 200 um due to 'unlimited' scan time, in contrast, typical high-resolution scans *in vivo* are acquired at 600 um. Additionally, although fixation drains most of the blood remaining in cerebral vessels, one needs to take into account remaining artefacts when performing quantitative analyses of the T2\*w data. See [Fig. 3](#f0015){ref-type="fig"} for an overview of images obtained at 7 T.Fig. 3Overview of sequences included in the NABCA 7 T *ex vivo* pipeline. Images are from NABCA case 1 (see [Table 2](#t0010){ref-type="table"}). A sagittal 3D FLAIR. B-D T2\*-weighted scans at different resolutions. B 0.6 × 0.6 × 0.6 mm, C 0.3 × 0.3 × 0.3 mm, D 0.25 × 0.25 × 1mm.Fig. 3

2.5. Dissection protocols {#s0045}
-------------------------

After *in situ* MRI, the donor is transported to the morgue and craniotomy takes place. Just before brain removal, the pH of the cerebral spinal fluid (CSF) is measured as an indicator of agonal state ([@bb0210]). Then the brain, with cervical spinal cord, is delicately removed from the skull by the neuropathologist. Additionally, the pituitary gland is dissected from the sella turcica. The brain is weighted, carefully inspected and photographed from different angles. The autopsy assistants notes the neuropathologist\'s assessment of the brain\'s external vasculature (including circle of Willis) and surfaces (*e.g.* atrophy, softening). After this, the cerebellum and brainstem are removed from the cerebrum at the cerebral peduncles. Upon dissection of the brainstem, pigmentation of the substantia nigra (SN) and locus coeruleus (LC) are assessed and noted. The two hemispheres are subsequently split in two; the left hemisphere will be further dissected according to a snap frozen (liquid nitric oxygen) protocol, the right hemisphere will be stored in 4% formalin for four weeks and dissected after 7 T MRI. The same is done for the cerebellum and brain stem. We will briefly discuss both protocols in the following sections. All dissections are performed by an experienced neuropathologists and any salient details at autopsy are written down.

### 2.5.1. Snap frozen tissue dissection {#s0050}

The snap frozen tissue is stored at -80 °C and may be used for further molecular, biochemical, genetic and cellular analysis. Dissection protocol is based on the BrainNet Europe (BNE) protocol (<http://www.brainnet-europe.org>/ under "Results", then "Protocols"), and includes \~80 tissue excisions of \~40 brain regions of the cerebrum, cerebellum and brain stem (see supplementary Table 1). Additional to the protocol, two tissue blocks are dissected and snap frozen, one cortical and one cerebellar region. These will later be used to determine the RNA integrity number (RIN), as quality assessment of the frozen tissue ([@bb0275]).

### 2.5.2. Formalin fixed tissue dissection {#s0055}

When the formalin fixed right hemisphere is returned from 7 T MRI scanning, the hemisphere is rinsed to dispose of any Fomblin that may still be present. The meninges are carefully removed and the hemisphere is assessed and photographed from all directions with a ruler (any salient details are written down). A coronal cut is made caudal of the anterior commissure, then slices of 0.5 cm thickness are made in both directions ([Fig. 4](#f0020){ref-type="fig"}). The formalin fixed dissection protocol includes \~35 regions (see supplementary Table 2). The protocol includes regions for pathological diagnosis (see paragraph 2.6), but is further extended to address specific research needs from researchers requesting tissue from NABCA. The formalin fixed dissected tissue blocks are put in cassettes and are paraffin embedded.Fig. 4Overview of a formalin fixed right hemisphere before slice dissection (top) and after dissection into slices. Beginning at the top left, ending at bottom right are 0.5 cm consecutive slices starting at the frontal cortex and moving posteriorly.Fig. 4

2.6. Neuropathological diagnosis {#s0060}
--------------------------------

The last part of the NABCA pipeline involves obtaining a neuropathological diagnosis to ensure they can be considered non-neurological ([@bb0240]). An extensive pathological assessment is done to obtain an overview of age-related or disease-related cellular changes.

From the formalin-fixed dissection, 15 regions (see supplementary Table 3) are selected, and series of 10 × 6-μm-thick sections are cut and mounted onto glass slides. These regions are then stained with (immuno)histochemistry. Manual staining is done for hematoxylin--eosin (HE) for gross anatomical inspection and (micro)infarctions, Congo Red and Gallyas silver staining for plaques, tangles and other inclusions. Automatic staining is done with Ventana Benchmark Ultra (Roche Diagnostics, Mannheim, Germany), with prediluted primary antibodies against hyper phosphorylated (p-)tau for aggregates (including pretangle neurons, neurofibrillary tangles, neuritic plaques, neuropil threads, and dystrophic neurites), α-synuclein to identify Lewy bodies and Lewy-related neurites, Amyloid-β for amyloid deposits, TAR DNA-binding protein 43 (TDP-43) to detect intraneuronal inclusions, and ionized calcium-binding adapter molecule 1 (Iba1) for presence of microglia (see [Table 2](#t0010){ref-type="table"} for an overview and details).Table 2Technical details of the (immuno)histopathological staining for pathological diagnosis.Table 2PrimarySupplierCloneDilutionAntigen retrieval methodNissl (Thionine)Thermo Fisher Scientific------HEKlinipath/Q-path------CongroredVWR------GallyasMerck KGaA------Anti-Aβ A4Dako6f/3d1:25CC1: Ventana Benchmark UltraAnti-TauInnogeneticsAT81:10.000CC1: Ventana Benchmark UltraAnti-α-SynucleinBD Biosciences421:5.000CC1: Ventana Benchmark UltraTDP-43cosmobiopoly1:1000CC1: Ventana Benchmark UltraIba1Wako Industriespoly1:4000CC1: Ventana Benchmark Ultra[^6]

Pathological assessment is done by an experienced neuropathologist (A.R.) who is blinded to clinical and MRI findings. With the above mentioned staining protocol, an assessment and distinction is made regarding AD-related pathologies, α-synuclein pathologies, TDP-43 pathology, hippocampal sclerosis, vascular pathologies and mixed pathologies ([@bb0020], [@bb0025], [@bb0030]; [@bb0015]; [@bb0210]; [@bb0230]). The extent of AD-related neuropathological burden is summarized by an 'ABC score' according to the 2012 NIA-AA guidelines ([@bb0165]; [@bb0215]), which is a composite of 3 scores: (A) stands for Amyloid plaque Thal phase ([@bb0300]), (B) stands for Braak stage of NFTs ([@bb0065]), and (C) stands for Consortium to Establish a Registry for Alzheimer\'s disease (CERAD) score of neuritic plaques ([@bb0165]). Each criteria is scored on a four-point scale between 0 (no pathology present) and 3 (highest phase/stage/score), and a combination of A, B and C scores represent a 'not', 'low', 'intermediate' or 'high' level of AD-related neuropathological change. An 'intermediate' or 'high' neuropathological change is considered indicative for AD ([@bb0165]; [@bb0215]). For staging and typing of Lewy body related α-synuclein pathology, a combination of Braak staging 1 to 6 ([@bb0070]) and McKeith typing of brainstem, limbic, neocortical and amygdala-predominant categories ([@bb0200]) is applied, as proposed by BNE ([@bb0025]). Additionally, brain tissue was also inspected for other salient pathology such as age-related tau astrogliopathy (ARTAG) ([@bb0195]), cerebral white matter rarefactions, cerebral amyloid angiopathy (CAA) and (micro)infarctions and hemorrhages and TDP pathology ([@bb0230]).

NABCA cut-off scores for inclusion as a non-neurological control based on pathology are an 'not' or 'low' classification of AD-related neuropathological change (an 'ABC score' lower than A1 B2 C2), the occurrence of Lewy body pathology higher than Braak stage 3 out of 6 for alphasynucelinopathy (limbic and neocortical), or other salient pathology such as metastases and infarctions or hemorrhages.

2.7. APOE genotyping {#s0065}
--------------------

For genotyping, 25 mg of tissue is cut from snap-frozen tissue blocks and used for DNA isolation. Frozen material is purified with the PureLink Genomic DNA mini kit (Invitrogen, Carlsbad, California, USA) according to manufacturer\'s protocol. DNA is eluted in 100 μl H~2~O and concentration and quality of eluted DNA is measured by nanodrop (ND-1000 spectrometer, Thermo Fisher Scientific Inc., Wilmington, Delaware, USA). Sequencing is performed using Sanger sequencing on an ABI130XL. Subjects are classified as homo- or heterozygote APOEε2, APOEε3 or APOEε4 carriers.

3. Overview of selected cases {#s0070}
=============================

To exemplify our pipeline, we have selected five NABCA cases and have put the clinical, MRI, pathological and genotyping data together (see [Table 3](#t0015){ref-type="table"}). On MRI only some mild global or local hippocampal atrophy and mild to moderate vascular white matter changes were observed. Pathologically, the ABC score was not suggestive of Alzheimer pathology for any of the cases. Additionally, case 1 showed some tauopathy in the amygdala, suggestive of ARTAG. Case 4 showed very early stages of α-synucleinopathy (incidental Lewy body pathology), but not enough for a Braak α-syn Stage 1. Case 5 showed a few small cortical infarctions. In summary, these cases showed only minimal age-related changes and can be considered non-neurological controls.

4. Storage and distribution of data and tissue {#s0075}
==============================================

4.1. Database {#s0080}
-------------

NABCA has developed a database and infrastructure for data management. After each autopsy, the database is updated and standardized forms are filled in regarding autopsy details. When more information becomes available about the clinical history, MRI report or pathological diagnosis, this is added to the database. This way, a comprehensive and integrated overview of demographic information (excluding any personal data of the donor), a summary of the medical history, MRI and pathological data is available, as well as an inventory of the snap-frozen and formalin-fixed tissue blocks that were excised. In the near future records of (pending) tissue requests and shipments will be added. Comprehensive search queries can generate various data reports for an overview of available information and tissue. The database is backed up automatically and stored on a secure server. Paper copies of dissection records are saved in a locked filing cabinet.

4.2. Security, privacy and anonymization of data {#s0085}
------------------------------------------------

NABCA works with linked anonymized donors, meaning, family name or other personal data (*e.g.* date of birth or address) of the donor is only available to the head of the morgue (for the human bequest program; information stored in a locked cabinet) and never to people working with NABCA (including CEO, coordinator and on call teams). To NABCA donors are anonymous ID numbers with limited information as shown in [Table 3](#t0015){ref-type="table"}. Regarding MRI scans, brain scans are unique and could allow for identification of the individual ([@bb0075]), therefore further de-identification of MRI data is applied. Image header information is removed ([@bb0260]), and either defacing ([@bb0205]), or brain extraction methods ([@bb0175]) are applied before distribution.

4.3. Website {#s0090}
------------

NABCA has a website (<http://nabca.eu>) where contact information and information regarding the application process can be found. In the future, the website will also feature a list with publications that have used NABCA MRI and/or tissue.

4.4. Distribution of data and tissue {#s0095}
------------------------------------

Requests for MRI data or tissue can be done through an application form. The application form requires information regarding general information of the applicant, content of the project (summary, background, deliverables, duration), a statement on how the project applies to NABCA objectives, project funding source and possible collaboration with for-profit organizations. Additionally, an overview of the requested data/tissue (number of donors, age range, gender, specific MRI sequences, specific tissue type and locations) is required. This will briefly be reviewed by the NABCA coordinator for completeness and general feasibility/availability. The application will then be sent to NABCA\'s scientific advisory board which will assess the application based on 1) scientific merit (design, methods, analysis). 2) If the research is in line with the objectives that NABCA is pursuing (see below). 3) originality/innovation. 4) suitability of requested data/tissue (regions, suitable number of donors). The Scientific Advisory Board generally responds with their advice within two weeks after the application has been submitted. Their advice could be to grant the application, grant the application if a few additional points are elucidated, or reject the application in its current form. If the application is rejected, a reason is given. After the Scientific Advisory Board, the application is reviewed by the Institutional Review Board. If their advice is positive, a Material Transfer Agreement (MTA) is signed by both parties, and data/tissue is allocated. Payments are set up to cover replacing of brain tissue with new cases, shipment and handling costs. NABCA has a not-for-profit financial model, there is no monetary gain for staff or institute involved.

5. Discussion, conclusions and future prospects {#s0100}
===============================================

NABCA\'s vision is to create a cutting-edge repository of post-mortem non-neurological human brain tissue and post-mortem (ultra-)high-field MR imaging data to national and international researchers, academic and industry. This creates a foundation for the study of healthy aging and as controls for wide variety of neurological disorders, stimulating translational neurosciences, from molecule to mind.

The combination of post-mortem MRI and (immune)histopathology has already proven its great value in the study of prevalent neurodegenerative and neuro-inflammatory diseases ([@bb0050]; [@bb0080]; [@bb0135]; [@bb0145]; [@bb0185]; [@bb0180]; [@bb0190]; [@bb0225]; [@bb0310]). In multiple sclerosis (MS), validation of the pathological substrate of MRI signal changes has led to improvement and implementation of new MRI sequences ([@bb0140]), which in turn helped to improve diagnostic and prognostic accuracy ([@bb0120]). In Alzheimer\'s disease (AD), histopathological defined cerebral microinfarcts (CMIs) were first detected as hyperintense focal lesions on *ex vivo* 7 T MRI, then on *in vivo* 7 T MRI in the same study ([@bb0310]) and subsequently on *in vivo* 3 T MRI, which could be related to clinical phenotype (cognitive impairment) ([@bb0115]; [@bb0160]). Additionally, the combination of post-mortem MRI and histology has played a crucial role in creating and validating several (cortical and subcortical) anatomical atlases ([@bb0005]; [@bb0090]; [@bb0105]; [@bb0330]; [@bb0335]), or software packages ([@bb0085]). In the future, *in situ* MRI could play an essential role as an intermediate between *ex vivo* and *in vivo* registration and validation ([@bb0325]). Additionally, studies regarding validation of new MRI sequences and development of MRI biomarkers will increase and continue to require post-mortem tissue validation. Lastly, the combination of molecular/biochemical, histopathological and 3D neuroanatomical (at macroscale and microscale) of the same donor allows answering questions regarding impact of molecular changes or pathological lesions on anatomical circuitry.

Nevertheless, some limitations can be mentioned about the pipeline. Donors enrolled for NABCA, or the body bequest program in general, may not be an accurate representation of the entire (Dutch) population. Due to personal or religious feelings, the population may lack some diversity. In addition, few young adult donors have been included to date. Information regarding the medical history may be limited or sometimes lacking (general practitioners have the right not to disclose patients\' information). The MRI sequences may be limited and not at par to a researcher\'s need, but NABCA continues to develop and include more advanced imaging techniques. Additionally, tissue quality is an important aspect and the RNA integrity number (RIN) of all specimens is collected. For biochemical and next-generation sequencing however other quality measures may need to be included.

In the future NABCA would like to (i) add morphometric data to imaging and histology, such as size, shape and distribution of neurons, axons and pathological hallmarks. (ii) Add more genotyping data such as amyloid precursor protein (APP), presenilin-1 (PS-1) and presenilin-2 (PS-2), leucine rich repeat kinase 2 (LRRK2), glucocerebrosidase (GBA), synuclein alpha (SNCA) multiplication and others ([@bb0060]). (iii) feed data (*e.g.* molecular information) from research teams using NABCA data back into the database (iv) lay the foundation for a unique platform for neuroanatomical, histopathological and neuroradiological education, of professionals, students and the general (lay) audience. For instance by organizing (summer)courses and lectures based on NABCA\'s multimodal datasets. Additionally, in the development of new ways of visualizing brain structure, NABCA is collaborating with researchers who are developing an app together with the gaming industry, VU University Medical Center\'s 3D Innovation Lab and a scientific team from Delft Technical University. This app will feature the multimodal (MRI, anatomy and molecular data) normal brain repository. Besides professionals and the scientific community, the general audience is extremely interested in brain science as well explaining the recent success of 'brain books' for the layperson and *e.g.* outreach organizations such as 'Brein in Beeld' (<http://breininbeeld.org>; outreach \~2500 people). The education of the scientific community and general public alike will not only improve the general knowledge on the aging human brain, but will also increase awareness of the importance of studying human tissue and brain banking in general.

In conclusion, the immense scope of modalities and techniques involved (*i.e.* molecular, cellular, network imaging) is unprecedented and NABCA forms a unique platform for translational neuroscience research and education.
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[^1]: *FLAIR* *= fluid attenuated inversion recovery; with optimized inversion times per case, due to differences in port-mortem delay and temperature/*

[^2]: *Echo-planar imaging (EPI) diffusion tensor imaging (DTI) with b-value 700 s/mm2, 30 gradient directions and 5 b0 reference scans.*

[^3]: *M* *=* *male, F* *=* *female, PMI* *=* *post-mortem interval, CSF* *= cerebrospinal fluid NBV* *=* *normalized brain volume, ABC score = score for* Aβ *deposition (A), for Braak stage of neurofibrillary degeneration (B) and neuritic plaque score (C), NFT* *= neurofibilary tangles, TDP* *= TAR DNA-binding protein, CAA* *= cerebral amyloid angiopathy, APOE = Apolipoprotein E, GCA* *=* *global cortical atrophy,BG* *= basal ganglia, NWMV* *=* *normalized white matter volume in litres (L), NGMV* *=* *normalized gray matter volume. n/a = not available.*

[^4]: *Normalized volumes obtained with SIENAX.*

[^5]: *Normalized volumes obtained with FIRST.*

[^6]: Aβ: amyloid-beta; HE: hematoxylin and eosin; Aβ: amyloid-beta; TDP: transactive response DNA-binding protein; Iba1: intracellular calcium binding protein-1; CC1: cell conditioning 1.
